Table 1 Treatment patterns among a prospective cohort of Malawian women with breast cancer, December 2016-October 2018, by stage at presentation

Overall Treatment Combinations:

No Treatment

1 (4)

3 (5)

1 (4)

Surgery alone

0 (0)

2 (4)

0 (0)

Chemotherapy Alone

1 (4)

20 (36)

23 (96)

Surgery and chemotherapy

11 (92)

29 (54)

0 (0)

Underwent Surgery as Modified Radical Mastectomy

11 (92)

31 (57)

0 (0)

Type of chemotherapy:

n = 12^#

n = 49^#

n = 23^#

Neoadjuvant alone, n (%)

1 (8)

22 (45)

--

Median number of cycles n (IQR)

6 (-)

3 (2–4)

Adjuvant alone, n (%)

5 (42)

7 (13)

--

Median number of cycles n (IQR)

6 (5–9)

6 (4–6)

Neoadjuvant and Adjuvant, n (%)

6 (50)

18 (33)

--

Median number of cycles n (IQR)

8 (7–9)

11 (10–13)

Palliative, n (%)

0 (0)

2 (7)

23 (100)

Median number of cycles n (IQR)

0 (0)

11 (9–12)

3 (1–9)

First chemotherapy regimen n (%)

n = 12^#

n = 49^#

n = 23^#

AC 9 (75)

T 13 (27)

Doc/Plat 8 (35)

T 2 (17)

AC 11 (22)

T 7 (30)

CAF 1 (8)

TAC 4 (8)

CAF 2 (9)

CAF 4 (8)

CMF 2 (9)

CMF 4 (8)

Other 4 (17)

TC 2 (4)

Other 11 (22)

Type of Neoadjuvant Chemotherapy Received:

n = 7

n = 40

Anthracycline

5 (71)

22 (55)

Taxane

1 (14)

12 (30)

Anthracycline + Taxane

1 (14)

5 (13)

Other

0 (0)

1 (2)

Initiated endocrine therapy (ever) if Hormone Receptor Positive n (%)

n = 10^{^}

n = 18^{^}

n = 13^{^}

3 (30)

8 (44)

4 (31)^%